CJC-1295
Also known as: Modified GRF(1-29), DAC:GRF
Long-acting GHRH analog that stimulates sustained growth hormone release.
Benefits
7
Conditions
5
Evidence
Clinical trials in healthy adults, ongoing research+ studies
Source
Synthetic GHRH analog
Gabriel Brain Score
Moderate
Overview
Long-acting GHRH analog that stimulates sustained growth hormone release.
Mechanism of Action
Binds GHRH receptors on pituitary somatotrophs, activates adenylyl cyclase/cAMP/PKA cascade, enhances GH gene transcription and protein synthesis, resists degradation for prolonged action (5.8-8.1 day half-life), produces 2-10-fold GH increases and 1.5-3-fold IGF-1 elevation.
Key Benefits
- ✓Increases growth hormone and IGF-1 levels
- ✓Enhances muscle growth and recovery
- ✓Improves body composition
- ✓Supports fat loss
- ✓Better sleep quality
- ✓Enhanced tissue repair
- ✓Improved skin quality
Clinical Applications
Dosing Guidelines
Subcutaneous injection
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
Clinical trials in healthy adults, ongoing research
Clinical evidence for sustained GH and IGF-1 elevation. Safety demonstrated in healthy adults. Long-term effects require further study.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Water retention
- •Increased hunger
- •Numbness/tingling
- •Fatigue
Contraindications
- Active cancer
- Diabetic retinopathy
- Pregnancy
- Breastfeeding
Interactions
- ⚠May affect glucose metabolism
- ⚠Caution with insulin
Quick Facts
Related Peptides
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Hexarelin
Potent hexapeptide ghrelin mimetic with strong GH-releasing effects and cardioprotective properties.
Sermorelin
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.